Welcome to our dedicated page for Korro Bio SEC filings (Ticker: KRRO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Korro Bio, Inc. filings document the regulatory record of a biopharmaceutical company developing RNA-editing genetic medicines through its OPERA® platform. Its 8-K reports disclose operating and financial results, corporate presentations, clinical and regulatory program updates, capital-structure activity, and material events tied to its RNA-editing pipeline.
The company’s filings also cover proxy governance, executive compensation, equity incentive and inducement arrangements, employment agreements, and material collaboration and license agreements. Program-related disclosures focus on KRRO-121, hyperammonemia in urea cycle disorders and hepatic encephalopathy, GalNAc-conjugated oligonucleotide research, alpha-1 antitrypsin deficiency, risk factors, and the financing and governance framework supporting Korro Bio’s development-stage operations.
Korro Bio reported an insider equity award to its Senior Vice President, Finance. On December 15, 2025, the officer received 21,482 shares of common stock issuable upon settlement of a restricted stock unit (RSU) grant at a reported price of $0.00 per share under the company’s 2023 Stock Option and Incentive Plan.
The RSUs will vest in two equal installments: 50% on June 15, 2026 and 50% on December 15, 2026, provided the officer maintains a continuous Service Relationship as defined in the plan through each vesting date. Following this grant, the reporting person beneficially owns 21,482 shares of Korro Bio common stock issuable upon RSU settlement, held directly.
Korro Bio announced multiple changes. The company and Novo Nordisk agreed to pause their research collaboration and license agreement for 12 months. During this hold period, all research and development obligations are suspended without liability or payment for either party, and Korro will wind down related activities. Novo Nordisk will reimburse certain wind-down costs, while confidentiality, exclusivity, termination terms, and Novo Nordisk’s substitution right remain in effect.
Korro implemented a strategic restructuring, reducing its workforce by approximately 34%. It estimates $2.4 million in one-time restructuring charges, mostly expected in the quarter ending December 31, 2025. Chief Medical Officer Olukemi A. Olugemo, M.D. resigned effective November 12, 2025, and will advise for three months; the post-termination option exercise period for vested options is extended through April 30, 2027. Korro also furnished a press release with financial results for the quarter ended September 30, 2025.
Korro Bio reported that Chief Financial Officer Vineet Agarwal plans to resign effective October 17, 2025 to pursue another opportunity. He has agreed to remain available as an advisor for 30 days to help with the transition. His separation is being handled under his November 2023 employment agreement, with a Separation Agreement providing benefits outside a change in control context, and his vested stock options as of October 17, 2025 may be exercised through March 31, 2027. The company states his departure is not due to any disagreement over management, operations, policies, or practices.
The board has appointed President and Chief Executive Officer Ram Aiyar to serve additionally as interim Chief Financial Officer and principal financial officer starting October 17, 2025. He will not receive additional compensation for these interim duties, and the company notes there are no special arrangements, family relationships, or related-party transactions tied to his appointment. The Separation Agreement with Mr. Agarwal is filed as an exhibit.
Korro Bio received a Schedule 13G/A disclosing that members of the Point72/Steven A. Cohen group collectively beneficially own 816,905 shares, representing 8.7% of Korro Bio's common stock as of the close of business on June 30, 2025. The filing breaks ownership across affiliated entities: Point72 Asset Management and Point72 Capital Advisors each report shared voting and dispositive power over 540,074 shares (5.8% each at the reporting-person level), while certain Point72 affiliates each report 276,831 shares (2.9%). No reporting person claims sole voting or dispositive power; the filing states the holdings were not acquired to change or influence control.
Korro Bio, Inc. Schedule 13G/A shows Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin jointly report beneficial ownership of 277,966 common shares, equal to 2.96% of the company's outstanding common stock. The filers report no sole voting or dispositive power and shared voting and dispositive power for the full amount, and include a certification that the shares were not acquired to change or influence control. The percentage is calculated using 9,390,492 shares outstanding as referenced in the issuer's disclosure.
AllianceBernstein L.P. reports beneficial ownership of 7,700 shares of Korro Bio Inc. common stock, representing 0.1% of the class. The filing states AllianceBernstein has sole voting and sole dispositive power over all 7,700 shares and holds the position in client discretionary investment advisory accounts for investment purposes. The filing notes AllianceBernstein is majority owned by Equitable Holdings but operates under independent management and that Equitable reports ownership separately. The statement affirms the position was not acquired to influence control of Korro Bio.
Korro Bio reported clinical progress alongside continued cash burn. The company recognized $4.0 million of collaboration revenue from Novo Nordisk and reported dosing of first participants in its Phase 1/2a REWRITE trial of KRRO-110 for Alpha-1 Antitrypsin Deficiency, with interim single-ascending dose data expected in the second half of 2025 and orphan drug designations from the FDA and EMA. As of June 30, 2025 the company held $119.6 million of cash, cash equivalents and marketable securities, which management expects will fund operations into 2027.
However, losses remain significant: net loss was $49.2 million for the six months ended June 30, 2025 and the accumulated deficit was $315.7 million. Management executed a 19% workforce reduction and recorded severance charges. The balance sheet shows total assets of $180.4 million and operating lease liabilities with a present value of $44.6 million. The company states additional financing may be required to continue development.
Korro Bio, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 as Exhibit 99.1 to a Form 8-K and included a Cover Page Interactive Data file as Exhibit 104. The Form 8-K states the press release is being furnished and expressly notes that the information, including Exhibit 99.1, is not to be deemed "filed" for purposes of Section 18 of the Securities Exchange Act.
The 8-K itself contains no financial figures or tables; readers must review Exhibit 99.1 for the company’s reported results. The report also confirms Korro’s common stock trades under the symbol KRRO on The Nasdaq Capital Market.